Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
August 20, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals in the U.S. died from drug overdose...
Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights
August 19, 2024 06:00 ET
|
Tonix Pharmaceuticals Holding Corp.
On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024 FDA granted Fast Track designation for TNX-102 SL for...
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
August 16, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
World Health Organization (WHO) has declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) 1 Tonix’s live virus vaccine candidate, TNX-801,...
Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit
August 13, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain
August 12, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Bedtime TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in the Phase 3 RESILIENT study resulted in statistically significant improvement in the primary endpoint of fibromyalgia nociplastic pain...
Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
August 06, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
High-throughput, high-content imaging-based assay developed to screen convalescent sera for neutralizing antibodies to SARS-CoV-2 variants Study highlights Tonix’s internal R&D...
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
July 31, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Fibromyalgia is a “diagnosable condition” in people suffering from Long COVID according to NASEM1 Diagnosing fibromyalgia in Long COVID patients is expected to expand the potential...
Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
July 30, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia, including improvement in pain and sleep quality Tonix granted FDA Fast Track...
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
July 25, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
July 10, 2024 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...